Revolutionizing Lung Cancer Diagnostics with eyonis TM LCS: Cutting-edge AI/ML Technology-based SaMD for Enhanced Patient Care

摘要

In recent years, the use of AI/ML technologies in the medical device industry has increased significantly, with a boom in the radiology sector. AI/ML-tech based Software as Medical Devices (SaMD) support healthcare professionals in their clinical routine, saving medical time, decreasing workload while improving image readouts. But more importantly, AI/ML technologies offer the ability to extract valuable and reliable insights from medical images, catching the unseen and paving the way for medical breakthroughs while improving the care pathway for diseases monitored by medical images. A striking example is the use of AI/ML technologies in the management of lung cancer, the world's deadliest cancer. Most lung cancer patients are diagnosed at an advanced stage of the disease, when they cannot be cured anymore. Enabling to accurately identify the malignant vs benign status of a nodule based on CT scan images, AI/ML technologies allow diagnosis of the disease at its earliest onset, when patients can still be cured. Introducing AI in radiology changes lung cancer patients' prognostic and can help save millions of lives globally. Median Technologies develops eyonisTM, a suite of unique end-to-end AI/ML technology-based CADe/CADx SaMD that automatically integrates and optimizes the entire medical imaging interpretation workflow, aiding radiologists and clinicians in the screening, diagnosis at the earliest stage and clinical management of cancer patients. eyonis? most advanced and flagship clinical development program is eyonis? Lung Cancer Screening (LCS) [1][2], a next-generation AI/ML tech-based SaMD providing Computer-Aided Detection (CADe) and Computer-Aided Diagnosis (CADx) [3][4] features for very early lung cancer diagnosis in lung cancer screening procedures [5]. The presentation will detail the evolution of eyonisTM LCS, from initial proof of concept to full SaMD.